Screening Tool to Identify the Dominant Pain Mechanism in Cancer Survivors: PainsCan — PainsCan  

Cancer Pain Clinical Trial

Official title: Development and Validation of a Screening Tool to Identify the Dominant Pain Mechanism in Cancer Survivors With Persistent Pain

Status Completed

Clinical Trial Summary

Development and internal validation of an easy-to-use tool for clinical pain assessment. The tool has to be applicable in any clinical practice and without the need for expensive and complicated hospital tools to identify the source of persistent pain after the treatment of cancer.

Clinical Trial Description

An adequate selection of physiotherapy treatment for persistent pain after the treatment of cancer, depends highly on the mechanism of the pain.

Pain can arise from a damaged nerve or tissue (skin, lymphatic system...). But when pain becomes chronic, alterations to the central nervous system can occur, as regulations of the facilitating and inhibiting mechanisms. These alterations may cause central sensitization pain. The body is now sensitized and cannot distinct harmful from harmless stimuli.

Each type of pain requires a specific treatment, therefore identification of the pain mechanism is crucial. Up till now, expensive and complex tests were performed in a hospital setting to determine if a patient suffers from neuropathic, nociceptive or central sensitization pain. This study aims for developping an assessment tool that does not require expensive devices but can be easily performed by any physiotherapist, within the timeframe of a standard consultation. ;

Related Conditions & MeSH terms

• Cancer Pain
• Cancer Survivors

• NCT number: NCT03981809
• Study type: Observational [Patient Registry]
• Source: Universitaire Ziekenhuizen KU Leuven
• Status: Completed
• Start date: June 13, 2019
• Completion date: December 30, 2022